StoxPiramal Pharma vs Cohance Lifesciences: share price & financials comparison
NSE: PPLPHARMA vs COHANCE · Healthcare · as of 13 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Piramal Pharma vs Cohance Lifesciences at a glance
Piramal Pharma (PPLPHARMA) has a market capitalisation of ₹32,484 Cr, against ₹17,546 Cr for Cohance Lifesciences (COHANCE). Over the past year Piramal Pharma has returned +22.0%, compared with -38.3% for Cohance Lifesciences. Cohance Lifesciences earns a higher return on equity (1.2% vs -2.6%). Piramal Pharma comes out ahead on valuation, momentum and technicals. Cohance Lifesciences comes out ahead on size, profitability and financial health. Across the scored metrics below, Piramal Pharma leads on 8 and Cohance Lifesciences on 5. On StoxGud's 10-point checklist, Piramal Pharma scores 6/10 and Cohance Lifesciences scores 5/10.
| Metric | Piramal Pharma | Cohance Lifesciences |
|---|---|---|
| Size | ||
| Market cap | ₹32,484 Cr | ₹17,546 Cr |
| Revenue (latest FY) | ₹8,869 Cr | ₹2,269 Cr |
| Net profit (latest FY) | ₹-326 Cr | ₹179 Cr |
| Valuation | ||
| P/E | — | 370.4 |
| P/B | 3.99 | 4.48 |
| Dividend yield | 0.06% | — |
| Profitability | ||
| Return on equity | -2.6% | 1.2% |
| Net profit margin | -2.1% | 2.3% |
| Operating margin | 12.3% | 11.2% |
| Growth | ||
| Revenue growth (YoY) | +28.1% | -14.2% |
| Net profit growth (YoY) | — | -79.5% |
| Revenue CAGR (multi-year) | +7.8% | +18.2% |
| Financial health | ||
| Debt to equity | 0.70 | 0.06 |
| Momentum | ||
| 1-month return | +24.8% | +4.9% |
| 1-year return | +22.0% | -38.3% |
| 3-year CAGR | +26.7% | -7.4% |
| 5-year CAGR | — | -2.3% |
| Distance from 52W high | -0.7% | -36.6% |
| Technicals | ||
| RSI (14) | 86 | 53 |
| Price vs 200-day avg | +35.6% | +11.8% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Piramal Pharma | Cohance Lifesciences |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✗ |
| Net profit margin above 10% | ✗ | ✗ |
| P/E below industry median | ✗ | ✗ |
| Score | 6/10 | 5/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Piramal Pharma or Cohance Lifesciences?
Piramal Pharma has a market cap of ₹32,484 Cr and Cohance Lifesciences has a market cap of ₹17,546 Cr as of 13 Nov 2026.
Which gave better returns in the last year, Piramal Pharma or Cohance Lifesciences?
Piramal Pharma did better: Piramal Pharma returned +22.0% and Cohance Lifesciences returned -38.3% over one year.
What is the difference between Piramal Pharma and Cohance Lifesciences?
Both are NSE-listed companies in Healthcare. Piramal Pharma is about 1.9 times the size of Cohance Lifesciences by market cap. In the latest financial year Piramal Pharma reported revenue of ₹8,869 Cr and Cohance Lifesciences ₹2,269 Cr. Operating margin is 12.3% for Piramal Pharma and 11.2% for Cohance Lifesciences. Debt to equity is 0.70 for Piramal Pharma and 0.06 for Cohance Lifesciences.
Which is better, Piramal Pharma or Cohance Lifesciences?
It depends on what you are looking for, and StoxGud does not recommend either stock. On the metrics compared above, Piramal Pharma leads on 8 and Cohance Lifesciences on 5. Piramal Pharma is ahead on valuation, momentum and technicals. Cohance Lifesciences is ahead on size, profitability and financial health. On StoxGud's rules-based checklist Piramal Pharma scores 6/10 and Cohance Lifesciences scores 5/10. This is information, not advice: consult a SEBI-registered adviser before investing.